Cargando…

Discovery of lixisenatide analogues as long-acting hypoglycemic agents using novel peptide half-life extension technology based on mycophenolic acid

Noncovalent binding of peptides to human serum albumin protects against renal clearance and enzymatic degradation. Herein, we investigated the effect of mycophenolic acid (MPA) albumin binders for improving the stability of peptides. For proof-of-principle, the short acting glucagon-like peptide-1 (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Chunli, Li, Qing, Deng, Xiaoyan, Wu, Weiwei, Liao, Liufeng, Liang, Kai, Huo, Rongrui, Li, Chenglin, Han, Jing, Tang, Weizhong, Jiang, Neng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Royal Society of Chemistry 2020
Materias:	Chemistry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9050719/ https://www.ncbi.nlm.nih.gov/pubmed/35496622 http://dx.doi.org/10.1039/d0ra01002b

Ejemplares similares

Lixisenatide as add-on therapy to basal insulin
por: Brown, Dominique Xavier, et al.
Publicado: (2013)

Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance
por: Whyte, Martin B, et al.
Publicado: (2018)

Hypoglycemic and beta cell protective effects of andrographolide analogue for diabetes treatment
por: Zhang, Zaijun, et al.
Publicado: (2009)

ACT-A: half empty or half full?
por: Shisana, Olive, et al.
Publicado: (2022)

Low incidence of gastrointestinal adverse events over time with a fixed‐ratio combination of insulin glargine and lixisenatide versus lixisenatide alone
por: Trujillo, Jennifer M., et al.
Publicado: (2018)

Hypoglycemic encephalopathy with extensive brain injuries: A case report
por: Hamid, Mohamed, et al.
Publicado: (2023)

Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post‐meal glucose excursions and glucagon in type 1 diabetes patients
por: Ballav, Chitrabhanu, et al.
Publicado: (2020)

Corticosteroids and mycophenolic acid analogues in immunoglobulin A nephropathy with progressive decline in kidney function
por: Huerta, Ana, et al.
Publicado: (2021)

Spiroindolone Analogues as Potential Hypoglycemic with Dual Inhibitory Activity on α-Amylase and α-Glucosidase
por: Altowyan, Mezna Saleh, et al.
Publicado: (2019)

Extensive herpes zoster involvement following mycophenolate mofetil therapy for sarcoidosis
por: Hegde, Sandhya, et al.
Publicado: (2011)

Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects
por: Becker, Reinhard H. A., et al.
Publicado: (2015)

Hypoglycemic herbs and their action mechanisms
por: Hui, Hongxiang, et al.
Publicado: (2009)

Simultaneous Versus Sequential Initiation of Lixisenatide and Basal Insulin for Type 2 Diabetes: Subgroup Analysis of a Japanese Post-Marketing Surveillance Study of Lixisenatide (PRANDIAL)
por: Kaneto, Hideaki, et al.
Publicado: (2022)

Evaluation of mulberry leaves’ hypoglycemic properties and hypoglycemic mechanisms
por: Chen, Sikai, et al.
Publicado: (2023)

Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes
por: Barnett, Anthony H
Publicado: (2011)

Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies
por: Wohlfart, Paulus, et al.
Publicado: (2013)

Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment
por: Hanefeld, Markolf, et al.
Publicado: (2017)

The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy
por: Oezer, Kuebra, et al.
Publicado: (2023)

Comparison of Renal Responses Between Continuous Mycophenolate Mofetil and Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Lupus Nephritis
por: Liao, Yu-Wan, et al.
Publicado: (2022)

Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
por: Petersen, Andreas B, et al.
Publicado: (2013)

Bioactives of Momordica charantia as Potential Anti-Diabetic/Hypoglycemic Agents
por: Xu, Bilin, et al.
Publicado: (2022)

New Hypoglycemic Drugs: Combination Drugs and Targets Discovery
por: Ni, Xiayun, et al.
Publicado: (2022)

Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials
por: Blonde, Lawrence, et al.
Publicado: (2016)

Austrian Experience with Lixisenatide Under Real-Life Conditions: A Prospective Observational Study
por: Brath, Helmut, et al.
Publicado: (2019)

A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes
por: Barrientos‐Pérez, Margarita, et al.
Publicado: (2022)

Mycophenolate-mofetil/mycophenolic-acid: COVID-19: 4 case reports
Publicado: (2021)

Hypoglycemic effect and mechanism of honokiol on type 2 diabetic mice
por: Sun, Jing, et al.
Publicado: (2015)

Novel Antioxidant and Hypoglycemic Water-Soluble Polysaccharides from Jasmine Tea
por: Tang, Yayuan, et al.
Publicado: (2021)

Exposure to Mycophenolate and Fatherhood
por: Midtvedt, Karsten, et al.
Publicado: (2017)

Propensity‐score‐matched comparative analyses of simultaneously administered fixed‐ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes
por: Rosenstock, Julio, et al.
Publicado: (2018)

Sites of gastrointestinal lesion induced by mycophenolate mofetil: a comparison with enteric-coated mycophenolate sodium in rats
por: Jia, Yichen, et al.
Publicado: (2018)

Prescription patterns of long-acting somatostatin analogues
por: Machado-Alba, Jorge Enrique, et al.
Publicado: (2017)

Pharmacokinetics of Mycophenolic Acid after Intravenous Administration of Mycophenolate Mofetil to Healthy Cats
por: Slovak, J.E., et al.
Publicado: (2017)

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis
por: Hunter, Kerry, et al.
Publicado: (2012)

Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis
por: Seino, Hiroaki, et al.
Publicado: (2016)

Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes
por: Ericsson, Åsa, et al.
Publicado: (2018)

A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide
por: Frias, Juan P., et al.
Publicado: (2018)

The hypoglycemic side of hypothyroidism
por: Kalra, Sanjay, et al.
Publicado: (2014)

Characteristics Predictive for a Successful Switch from Insulin Analogue Therapy to Oral Hypoglycemic Agents in Patients with Type 2 Diabetes
por: Kim, Gyuri, et al.
Publicado: (2016)

Silver-promoted solid-phase guanidinylation enables the first synthesis of arginine glycosylated Samoamide A cyclopeptide analogue
por: Liang, Bingxin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_oemmods31brif99u0ruse0gig9